• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BioNTech SE - American Depositary Shares (NQ:BNTX)

    97.12 +0.72 (+0.75%)
    Streaming Delayed Price Updated: 3:45 PM EDT, Sep 11, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 813,760
    Open 96.77
    Bid (Size) 97.10 (100)
    Ask (Size) 97.15 (100)
    Prev. Close 96.40
    Today's Range 96.00 - 97.90
    52wk Range 79.52 - 124.00
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Why Pfizer Stock Was so Healthy in August ↗
    The beaten-down pharmaceutical stock was revived after it posted an estimates-beating quarter. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now? ↗
    Both have attracted considerable attention from Wall Street recently. 
    Via The Motley Fool

    Performance

    YTD
    +0.4%
    +0.4%
    1 Month
    +4.7%
    +4.7%
    3 Month
    +8.5%
    +8.5%
    6 Month
    +7.8%
    +7.8%
    1 Year
    -3.8%
    -3.8%

    More News

    Read More
    News headline image
    Is BioNTech Stock a No-Brainer Buy on the Dip? ↗
    Via The Motley Fool
    BioNTech (NASDAQ:BNTX) Falls After Q2 Revenue Miss and Revised Full-Year Guidance ↗
    Via Chartmill
    News headline image
    Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
    From Pfizer Inc.
    Via Business Wire
    News headline image
    Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
    Via FinancialNewsMedia
    News headline image
    A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
    From MarketNewsUpdates.com
    Via GlobeNewswire
    News headline image
    BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
    From BioNTech SE
    Via GlobeNewswire
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    News headline image
    BioNTech Just Named a New CEO. Here's What Guido Oelkers' Appointment Means for the Stock. ↗
    Via The Motley Fool
    News headline image
    BioNTech (BNTX) Q2 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    BioNTech Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
    From Pfizer Inc.
    Via Business Wire
    News headline image
    European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring ↗
    Via The Motley Fool
    News headline image
    BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock ↗
    Via The Motley Fool
    Topics ETFs
    News headline image
    2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    2 Biotech Stocks Worth Buying Before Their Potential Buyouts ↗
    Via The Motley Fool
    News headline image
    Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
    From BioNTech SE
    Via GlobeNewswire

    Frequently Asked Questions

    Is BioNTech SE - American Depositary Shares publicly traded?
    Yes, BioNTech SE - American Depositary Shares is publicly traded.
    What exchange does BioNTech SE - American Depositary Shares trade on?
    BioNTech SE - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for BioNTech SE - American Depositary Shares?
    The ticker symbol for BioNTech SE - American Depositary Shares is BNTX on the Nasdaq Stock Market
    What is the current price of BioNTech SE - American Depositary Shares?
    The current price of BioNTech SE - American Depositary Shares is 97.12
    When was BioNTech SE - American Depositary Shares last traded?
    The last trade of BioNTech SE - American Depositary Shares was at 09/11/26 03:45 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.